Retrospective Real-World Outcomes for Patients With ALK-Rearranged Lung Cancer Receiving ALK Receptor Tyrosine Kinase Inhibitors

INTRODUCTION: This study explored the use, safety, and efficacy of initial use of an ALK-inhibiting targeted therapy (ALK tyrosine kinase inhibitor [TKI]) in patients with ALK-rearranged NSCLC in a population-based, real-world clinical population within the province of Alberta, Canada. METHODS: Demo...

Descripción completa

Detalles Bibliográficos
Autores principales: Gibson, Amanda J.W., Box, Adrian, Dean, Michelle L., Elegbede, Anifat A., Hao, Desiree, Sangha, Randeep, Bebb, D. Gwyn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474209/
https://www.ncbi.nlm.nih.gov/pubmed/34590010
http://dx.doi.org/10.1016/j.jtocrr.2021.100157

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474209/
https://www.ncbi.nlm.nih.gov/pubmed/34590010
http://dx.doi.org/10.1016/j.jtocrr.2021.100157

Ejemplares similares